Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 73Carcinoma, Renal Cell 36Urinary Bladder Neoplasms 25Carcinoma, Transitional Cell 14Neoplasm Metastasis 12Melanoma 12Ovarian Neoplasms 11Lung Neoplasms 11Colorectal Neoplasms 11Clear-cell metastatic renal cell carcinoma 10Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Wilms Tumor 8Ureteral Neoplasms 8Pancreatic Neoplasms 8Carcinoma, Hepatocellular 8Lymphoma, Non-Hodgkin 7Glioma 7Urethral Neoplasms 6Sarcoma 6Neuroblastoma 6Hepatoblastoma 6Uterine Cervical Neoplasms 5Rhabdoid Tumor 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Medulloblastoma 5Histiocytosis, Langerhans-Cell 5Ependymoma 5Central Nervous System Neoplasms 5

Interventions

Cisplatin 6pembrolizumab 5fludarabine 5Nivolumab 5Cyclophosphamide 5aldesleukin 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Radiotherapy 3Ipilimumab 3fludarabine phosphate 2entinostat 2cabozantinib 2avelumab 2aflibercept 2Specimen Handling 2CTLA-4 Antigen 2Biopsy 2Adoptive Transfer 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1ripretinib 1oncogene protein E7, Human papillomavirus type 16 1niraparib 1nimotuzumab 1lenvatinib 1enfortumab vedotin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Penile Neoplasms × Specimen Handling × Genitourinary × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡